Cancer Biomarkers

Blincyto First Drug Approved for ALL and the MRD Biomarker
Cancer BiomarkersFDA NewsLeukemiaNewsworthy
This is the first time the FDA has used minimal residual disease (MRD) as a biomarker to approve a specific treatment for patients with acute lymphoblastic leukemia (ALL).
What Are Biomarkers in Breast Cancer, and How Do They Affect My Treatment? Interview with Daniel F. Hayes, MD, FACP, FASCO
Breast CancerCancer BiomarkersCancer Screening
Dr Hayes, Immediate Past President of ASCO and Professor of Breast Cancer Research at the University of Michigan Comprehensive Cancer Center, explains how biomarkers offer more precise treatment opportunities for patients with breast cancer.
New Developments in Cancer Biomarkers Reported at AACR 2018
Cancer Biomarkers
Read about important advancements in tumor biomarkers and their role in guiding treatment in some types of cancer.
Growing Role of Biomarkers in the Treatment of Patients with Acute Myeloid Leukemia
Cancer BiomarkersLeukemia
In recent years, new treatments for acute myeloid leukemia have improved outcomes. In 2017, 2 new drugs were approved for patients with this type of blood cancer linked to a specific biomarker.
Understanding dMMR and MSI-H Tumor Biomarkers
Cancer Biomarkers
The understanding of the role of dMMR or MSI-H biomarkers in cancer has led to the first approval of a cancer drug based on a biomarker instead of a specific tumor type.
What Are Cancer Biomarkers, and Why Are They Important?
Cancer BiomarkersCancer Screening
Biomarkers are biologic markers that indicate changes in our genes and may increase the risk of cancer.
My Biomarker Story, and Why I Advocate for Genetic Testing
Patient AdvocacyPatient StoriesCancer Biomarkers
Wenora Y. Johnson, 3-time survivor, shares her cancer story and encourages patients to ask their care team about biomarker testing.
New Biomarker May Predict Risk for Uterine Cancer Recurrence
Web ExclusivesCancer Biomarkers
A new study that included 500 women with uterine cancer diagnosed between 1981 and 2007 led to the discovery of a biomarker that may be able to identify those who are at high risk for uterine cancer recurrence.

Results 1 - 8 of 8

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.